CC BY-NC-ND 4.0 · Laryngorhinootologie 2020; 99(S 02): S293
DOI: 10.1055/s-0040-1711204
Poster
Otology

Hypothermia as a potential therapeutic approach to reduce the risk of hearing loss and the need for a hypothermal device to investigate this question in a clinical study

Dominik Péus
1   HNO-Klinik, Universitätsspital Basel, Basel Switzerland
,
Daniel Bodmer
1   HNO-Klinik, Universitätsspital Basel, Basel Switzerland
› Author Affiliations
 
 

    The permanent bilateral hearing loss caused by ototoxic therapies is still an unsolved medical and socio-economic problem with a large impact on society and, of course, on private life and work productivity. Patients who receive a high dosed cisplatin regimen have at least a 50% risk of hearing loss. Most of the severe side-effects are under control nowadays but ototoxicity is still a major problem and even leads to discontinuation of anticancer therapy sometimes. The goal of a hypothermal approach will be a reduced cisplatin uptake in the inner ear and a reduction of cisplatin associated hearing loss. The efficacy of hypothermia was already shown in animal studies, but until now no clinical study has been carried out because the concept of hypothermia application to the inner ear is quite new and there are some problems in applying hypothermia to the inner ear of living human subjects. However, the current project overcomes these problems with the innovation of a custom-made channeled ear mold which will be connected to a cooling water circulation. The design has to address the following requirements: a very close contact to the ear canal and eardrum will be crucial towards an effective heat absorption, possible cooling duration of at least 1 hour, comfortable fit and must not harm the eardrum or the skin of the ear canal, and the production material has to be biocompatible. We present a prototype made of 3D printing of biocompatible flexible silicone. This prototype could be used for clinical studies to investigate the effect of hypothermia to reduce the risk of hearing loss during ototoxic therapies.


    #
    Péus Dominik
    HNO-Klinik, Universitätsspital Basel
    Petersgraben 4
    4091 Basel
    Switzerland   

    Publication History

    Article published online:
    10 June 2020

    © 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    © Georg Thieme Verlag KG
    Stuttgart · New York